| INTRODUCTION
The increasing number of patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) has become a major public health issue with large financial implications. Hemodialysis (HD), one of the modalities of renal replacement therapy, depends on long-term patency of vascular access to allow adequate dialysis. In clinical practice, the choice of hemodialysis vascular access includes arteriovenous fistula (AVF), arteriovenous graft (AVG) or central venous catheter (CVC). HD vascular access failure is one of the most important causes of morbidity and mortality and contributes to the cost of ESRD care. 1 The pathologic mechanisms of HD vascular access failure are multiple. Many risk factors such as diabetes, hypotension, insufficient surgical experience, higher level of uremic toxin, and decrease in heparin administration all had been documented to be related to poor outcome of vascular access. 2, 3 Besides, stenosis often develops in the venous segment of the AVF due to neointimal hyperplasia (NIH) and at the vein-graft anastomosis in AVG, which obstructs blood flow and thus leads to vascular access failure finally. 4 Increased expression of matrix metalloproteinase-9 secondary to extracellular matrix dysregulation may also cause structural instability of the neointimal layer and disorganize the overlying endothelial layer subsequently. 5 Inflammatory process has been proposed to play a pathologic role in NIH. Available data investigating the association between systemic inflammatory markers including high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor alpha and interleukin-6 (IL-6) and AVF dysfunction and demonstrated that all these systemic inflammatory markers were elevated in patients with AVF dysfunction even though AVF is a local tissue. 6 Indeed, inflammatory mediators, such as tumor necrosis factor alpha, fibroblast growth factor, and vasoactive and adhesion molecules can also integrate the proliferation of myofibroblasts and migration of smooth muscle cells, facilitate a process like atherosclerosis and give rise to vascular access stenosis or thrombosis. 7 Tintut et al. 8 Thus, the current study specifically aimed to investigate whether longitudinal change of CRP levels was associated with vascular access failure in HD patients.
| MATERIALS AND METHODS

| Study population and design
We conducted a retrospective study and enrolled patients with ESRD 
| Definition of HD vascular access failure and combined endpoint
The definition of HD vascular access failure was made clinically, based on the following criteria: the decrease or absence of palpable and au- 
| Statistical analysis
Statistical analysis was computerized using SPSS package for windows A P value of <.05 was considered to be statistically significant.
| RESULTS
| Subject characteristics
A total of 318 patients were enrolled in our study. Table 1 shows the demographics and baseline characteristics of all participants and the comparison among low hs-CRP group, high hs-CRP group and fluctuated hs-CRP group. The mean age of all participants was 64.2±10.9 years old and male patients account for 47% of total subjects. Among the patients, 72% had hypertension and 21% had diabetes mellitus. The mean dialysis vintage was 15.5±4.7 years. At enrollment, most of our subjects had AVF (83%), 14% had AVG and 3% had CVC.
| Comparison between low hs-CRP, high hs-CRP and fluctuated hs-CRP group
As shown in 7%. In fluctuated hs-CRP group, AVF: 80%, AVG: 17%, CVC: 3%.
There was no significant difference regarding the distribution of various vascular access (P=.315). BMI, body mass index; URR, urea reduction ratio; Intact PTH, intact parathyroid hormone; ALK-P, alkaline phosphatase; hs-CRP, high-sensitivity C-reactive protein.
a Median and interquartile range.
As shown in Table 3 , Cox regression analysis revealed that albumin (β=−1.414, 95% CI 0.113-0.526, P=.000) was an independent predictor for vascular access failure. Grouping of hs-CRP was not related to outcome of vascular access. However, association analysis found an inverse relationship between hs-CRP and albumin (r=−.339, P<.0001).
The duration from enrollment to the first vascular access failure episode among three CRP groups was compared and we found that vascular access failure rate was not different among the three groups (P=.091, Figure 1 ). Both fluctuated hs-CRP group and high hs-CRP group had shorter period than low hs-CRP group (P=.03 and .026).
No difference was noted between high and fluctuated hs-CRP groups.
| DISCUSSION
In the present study, we demonstrated that patients with different CRP groups in longitudinal observation were characterized by various demographic as well as laboratory data. The rate of annual vascular Low grade inflammation state is often present in patients with ESRD and serum markers of chronic inflammation are strongly related to survival in long-term HD patients. 13 Over a 7-year period, our study disclosed that most HD patients (67.3%) had fluctuated hs-CRP levels and less than one quarter patients (12.3%) were with persistent high hs-CRP levels. Our finding supported the emphasis on long-term monitoring of hs-CRP levels. Both diminished renal clearance and increased production, as a result of uremic factors, can lead to higher systemic concentration of pro-inflammatory cytokines. The causes of inflammatory reaction among dialysis patients are not fully understood. It had been postulated that incompatibility of the dialyzer membrane, infection, comorbidities, genetic factors and diet all can be the potential sources. 14 Available evidence suggested CRP level was an independent risk factor for AVF thrombosis and forecasted vascular access thrombosis. 15 Additionally, Chang et al. 5 reported that expression of vascular cell adhesion molecule-1, tumor necrosis factor alpha and IL-6 were increased in thrombosed AVF compared with non-thrombosed AVF.
T A B L E 2 Comparison between diabetic and non-diabetic groups
The authors concluded that marked inflammation was associated with thrombosed AVF. Furthermore, vascular calcification and endothelial dysfunction may also play some roles in the pathogenesis of dysfunction of AVF. It has been speculated that chronic inflammation and/or increased oxidative stress promote accelerated vascular calcification directly in dialysis patients. 16 One recent study indicated that low grade chronic inflammation transforms endothelium to a pro-inflammatory and pro-coagulant surface making the vasculature more susceptible to injury and endothelial dysfunction in patients with chronic kidney disease. 17 To the best of our knowledge, this is the first In the current study, we found the rate of angioplasty was higher in diabetic group but annual failure rate did not differ between diabetic and non-diabetic patients. Miller et al. 23 conducted a large prospective study of AVG thrombosis and found that diabetes was not a predisposing factor for this complication. Another study also suggested that diabetes was not a predictor for venous stenosis of AVF. 24 In contrast,
Afsar demonstrated that the presence of diabetes was independently related to primary AVF failure, possibly because diabetic patients were more likely to have increased thrombogenicity, impaired vasodilatation resulting from endothelial dysfunction and peripheral arterial disease. 25 In another study, Puskar et al. 2 found diabetes was one of the important factors affecting AVF survival. Difference in study period may explain the contradictory results of these studies. Second, glycemic control was crucial in diabetic patients and may affect failure rate.
F I G U R E 1 Kaplan-Meier curve for the free interval to the first vascular access failure episode in three groups showed vascular access patency rate was not different among the three groups (P=.091) but fluctuated hs-CRP group had shorter period than patients with low hs-CRP group (P=.030). Comparing with low hs-CRP group, patients with high hs-CRP developed the first failure episode earlier (P=.026). Group 1: low hs-CRP group; Group 2: high hs-CRP group; Group 3: fluctuated hs-CRP group It has been well documented that diabetic HD patients with optimal glycemic control had higher patency rate than patients with suboptimal glycemic control. 26 In our study, glycemic control in diabetic HD subjects was relatively acceptable with mean glycated hemoglobin 7.1% and no significant difference was observed among three groups.
Undoubtedly, because diabetic patients usually are with higher mortality rate, patients enrolled in our study might survive with lower cardiovascular risk. It is probable the selection bias affects study results.
In our study, Cox regression model found serum albumin level was the sole independent predictor for vascular access failure. Furthermore, association analysis revealed that there was an inverse relationship between hs-CRP and albumin. Another recent study had also shown the variability of CRP was also one of the powerful predictors for the levels of albumin. 27 Levels of albumin have long been recognized as an important prognostic factor of all-cause and cardiovascular mortality in hemodialysis patients. As we understand that albumin is not only a nutritional marker, but also an inflammatory marker, it is conceivable to accept that serum albumin was a significant outcome predictor of There remains several limitations in our study. First, as the current study was retrospective, it is not allowed to compare all factors that might affect outcome of vascular access. Second, because hs-CRP measurements were performed every 6 months for consecutive 7 years, occult inflammatory reactions such as periodontal disease 29 or chronic Chlamydia pneumoniae infections 30 during study period might be ignored and not detected. Third, due to small sample size, discrimination for the different locations of vascular access was not performed.
In conclusion, our study had demonstrated that HD patients with fluctuated hs-CRP level rather than high hs-CRP level were more likely to have higher vascular access failure rate. The rate of angioplasty for thrombosed vascular access was increased in diabetic patients. The free interval of vascular access dysfunction in patients with either high or fluctuated hs-CRP was shorter than those with low hs-CRP.
